Your browser is no longer supported. Please, upgrade your browser.
Passage Bio, Inc.
Index- P/E- EPS (ttm)-2.56 Insider Own0.60% Shs Outstand45.50M Perf Week10.04%
Market Cap1.03B Forward P/E- EPS next Y-3.27 Insider Trans-0.42% Shs Float45.31M Perf Month-3.74%
Income-86.40M PEG- EPS next Q-0.73 Inst Own70.40% Short Float4.34% Perf Quarter-14.64%
Sales- P/S- EPS this Y-4.50% Inst Trans3.57% Short Ratio4.27 Perf Half Y24.64%
Book/sh7.45 P/B2.66 EPS next Y-8.60% ROA- Target Price28.90 Perf Year0.41%
Cash/sh6.47 P/C3.06 EPS next 5Y- ROE- 52W Range8.09 - 38.23 Perf YTD-22.45%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.13% Beta-
Dividend %- Quick Ratio18.30 Sales past 5Y- Gross Margin- 52W Low145.12% ATR1.75
Employees20 Current Ratio18.30 Sales Q/Q- Oper. Margin- RSI (14)46.51 Volatility10.79% 8.40%
OptionableYes Debt/Eq0.00 EPS Q/Q-116.90% Profit Margin- Rel Volume0.81 Prev Close19.43
ShortableYes LT Debt/Eq0.00 EarningsMar 03 BMO Payout- Avg Volume460.58K Price19.83
Recom1.60 SMA20-1.68% SMA50-13.86% SMA200-3.77% Volume374,000 Change2.06%
Mar-04-21Upgrade Goldman Neutral → Buy $28 → $30
Feb-04-21Initiated Guggenheim Buy $25
Jan-25-21Initiated Wedbush Outperform $26
Jan-04-21Upgrade JP Morgan Neutral → Overweight $25 → $35
Dec-11-20Initiated Citigroup Neutral $28
Aug-14-20Downgrade JP Morgan Overweight → Neutral $25
Jun-25-20Downgrade Goldman Buy → Neutral $28
Mar-25-20Initiated Chardan Capital Markets Buy $30
Mar-24-20Initiated JP Morgan Overweight $25
Mar-24-20Initiated Goldman Buy $27
Mar-24-20Initiated Cowen Outperform
Mar-03-21 07:00AM  
Mar-02-21 04:01PM  
Feb-24-21 07:00AM  
Feb-19-21 07:00AM  
Feb-08-21 07:00AM  
Feb-04-21 12:04PM  
Jan-28-21 07:00AM  
Jan-22-21 02:22PM  
Jan-21-21 07:48PM  
Jan-19-21 04:06PM  
Jan-13-21 10:25AM  
Jan-11-21 07:00AM  
Jan-04-21 04:01PM  
Dec-16-20 08:00AM  
Dec-15-20 11:10PM  
Dec-11-20 08:11AM  
Dec-10-20 04:01PM  
Dec-07-20 07:00AM  
Nov-24-20 03:55AM  
Nov-23-20 04:01PM  
Nov-11-20 04:30PM  
Nov-10-20 07:00AM  
Nov-09-20 07:00AM  
Nov-04-20 07:00AM  
Oct-28-20 07:00AM  
Oct-26-20 07:00AM  
Oct-14-20 08:30AM  
Oct-13-20 04:30PM  
Oct-06-20 07:00AM  
Sep-25-20 07:00AM  
Sep-17-20 07:00AM  
Sep-03-20 08:00AM  
Aug-26-20 02:58PM  
Aug-13-20 07:00AM  
Aug-07-20 04:01PM  
Jun-26-20 08:00AM  
Jun-04-20 11:17AM  
May-28-20 08:35AM  
May-21-20 08:00AM  
May-12-20 05:00PM  
May-11-20 07:00AM  
May-07-20 07:30AM  
May-04-20 08:00AM  
Apr-21-20 08:00AM  
Apr-08-20 08:00AM  
Mar-27-20 08:00AM  
Mar-09-20 04:30PM  
Mar-05-20 08:00AM  
Feb-27-20 07:25PM  
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A, as well as programs for the treatment of adult CNS indication. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Quigley Jill M.Chief Operating OfficerJan 20Sale30.011,30039,011295,284Jan 22 05:54 PM